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Abstract
Lipid disorders are associated with atherosclerotic vascular disease, and therapy is
associated with a substantial reduction in cardiovascular events. Current approaches to the
treatment of lipid disorders are ineffective in a substantial number of patients. New therapies
for refractory hypercholesterolemia, severe hypertriglyceridemia, and low levels of high-
density lipoprotein cholesterol are needed: somatic gene therapy is one viable approach.
The molecular etiology and pathophysiology of most of the candidate diseases are well
understood. Animal models exist for the diseases and in many cases preclinical proof-of-
principle studies have already been performed. There has been progress in the development
of vectors that provide long-term gene expression. New clinical gene therapy trials for lipid
disorders are likely to be initiated within the next few years.
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AAV = adeno-associated virus; ABC1 = ATP-binding cassette protein 1; apoA-I = apolipoprotein A-I; apoE = apolipoprotein E; CETP = cholesteryl
ester transfer protein; FH = familial hypercholesterolemia; HDL = high-density lipoprotein; LAL = lysosomal acid lipase; LCAT = lecithin:cholesterol
acyltransferase; LDL = low-density lipoprotein; LPL = lipoprotein lipase; MTP = microsomal transfer protein; VLDL = very-low-density lipoprotein;
WHHL = Watanabe heritable hyperlipidemic.
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Introduction
A reduction in plasma cholesterol levels is associated with
a substantial reduction in cardiovascular events [1].
Methods for reducing cholesterol levels and specifically
low-density lipoprotein (LDL) cholesterol include lifestyle
changes and drug therapy, including statins, niacin, bile
acid sequestrants, and fibrates [2]. However, many
patients cannot achieve optimal LDL cholesterol levels with
existing cholesterol-lowering therapies [2]. The majority of
these patients have genetic disorders that cause severe
hypercholesterolemia that is partly refractory to existing
therapies, whereas other patients do not tolerate existing
therapies. Hypercholesterolemia therefore remains an
important target for the development of novel therapies.
Plasma triglycerides are increasingly recognized as a risk
factor for cardiovascular disease [3], and severe hyper-
triglyceridemia is associated with acute pancreatitis.
Although triglyceride levels can frequently be decreased
with a combination of lifestyle changes and drug therapy
such as fibrates and niacin, there remain a substantial
number of individuals in which triglycerides remain signifi-
cantly elevated. Hypertriglyceridemia is therefore also a
target for the development of novel therapies.http://cvm.controlled-trials.com/content/1/2/120
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Finally, low plasma levels of high-density lipoprotein (HDL)
cholesterol are associated with significantly increased car-
diovascular risk [4]. Low-HDL cholesterol is one of the
most common lipid disorders in patients with premature
coronary artery disease [5]. There are a variety of genetic
causes of low-HDL cholesterol [6]. A variety of data from
animals and from humans suggest that increasing the HDL
cholesterol concentration is beneficial. However, the major-
ity of patients have difficulty raising the HDL cholesterol
level despite lifestyle changes and drug therapy such as
niacin and fibrates. Low-HDL cholesterol is therefore a very
important target for the development of novel therapies.
There is much interest in the development of new small
molecules that decrease LDL cholesterol, decrease
triglycerides, or raise HDL cholesterol levels. In addition,
gene therapy has been considered as a potential
approach to some of these targets. The purpose of this
article is to review the specific lipid disorders that are
potential candidates for the development of clinical gene
therapy, to discuss the specific issues involved for these
disorders, to summarize the proof-of-principle studies in
animals where such studies exist, and to comment on the
potential progress toward clinical trials of gene therapy for
these disorders.
Lipid disorders that are candidates for gene
therapy
Disorders associated primarily with hypercholesterolemia
or hypertriglyceridemia
Familial hypercholesterolemia
Familial hypercholesterolemia (FH) is caused by mutations
in the LDL receptor [7]. Homozygous FH, owing to muta-
tions in both LDL receptor alleles, occurs in about 1 in one
million individuals worldwide and is associated with
markedly elevated LDL cholesterol levels (about
500–1000 mg/dl) and markedly premature atherosclerotic
cardiovascular disease. FH homozygotes are highly resis-
tant to currently available drug therapy. The preferred
treatment at present is LDL apheresis, a physical proce-
dure in which LDL is selectively removed from the blood
by passing plasma over columns that bind the LDL [8].
LDL apheresis must be performed every 1–2 weeks, and
although patients on regular apheresis seem to have
delayed onset and progression of atherosclerotic cardio-
vascular disease, they remain at a much higher than
average risk. For these reasons, homozygous FH is a can-
didate for the development of gene therapy.
Although LDL receptors are expressed ubiquitously, the
hepatic LDL receptor has the greatest quantitative effect
in controlling plasma LDL levels. Importantly, a limited
number of patients with homozygous FH have undergone
liver transplantation and have experienced substantial
reductions in LDL cholesterol levels. This indicates that
gene therapy targeted toward the liver would be likely to
be an effective therapy for this disease. The number of
hepatocytes and the level of gene expression necessary to
result in a therapeutic effect are uncertain. However, it is
worth noting that patients with homozygous FH are fre-
quently classified as either receptor-negative (no
detectable functional LDL receptor activity) or receptor-
defective (markedly reduced but detectable LDL receptor
activity). Receptor-negative FH is associated with signifi-
cantly higher cholesterol levels and earlier onset and
severity of atherosclerotic cardiovascular disease than
receptor-defective FH. A gene therapeutic approach that
resulted in enough LDL receptor expression to convert a
receptor-negative patient to ‘receptor-defective’ could
therefore be considered therapeutically beneficial.
A considerable number of proof-of-principle studies have
been performed in animal models of homozygous FH. The
Watanabe heritable hyperlipidemic (WHHL) rabbit is
homozygous for a natural mutation in the LDL receptor. A
recombinant retrovirus was used to achieve ex vivo gene
transfer of the rabbit LDL receptor to hepatocytes from
WHHL rabbits, with subsequent reinfusion of the geneti-
cally modified hepatocytes. Plasma cholesterol levels were
reduced by about 30% and persisted for 6 months [9].
Injection of a recombinant first-generation adenovirus
encoding the LDL receptor into WHHL rabbits transiently
reduced LDL cholesterol levels [10,11]. The LDL receptor
knockout mouse has also been used as an FH model. The
administration of a first-generation adenovirus encoding
the human LDL receptor transiently reduced LDL choles-
terol levels in chow-fed mice deficient in LDL receptor
[12] and reduced cholesterol levels and atherosclerosis in
mice deficient in LDL receptor that were fed with a diet
high in fat (M Kawashiri, DJ Rader, unpublished data).
Administration of antibody against CD40 ligand at the
time of administration on recombinant LDL receptor aden-
ovirus decreased immune-mediated promoter silencing
and resulted in long-term transgene expression and cho-
lesterol decrease in mice deficient in LDL receptor [13].
Although the LDL receptor is the logical gene to use for
gene therapy of FH, there is concern that the LDL receptor
expressed as a result of somatic gene transfer could be
immunogenic in patients that lack the ability to synthesize
the LDL receptor. Other genes have therefore been used in
animals in attempts to ameliorate the hypercholesterolemia
associated with a deficiency in LDL receptors. The very-
low-density lipoprotein (VLDL) receptor is a lipoprotein
receptor with homology to the LDL receptor, but it is not
normally expressed in the liver. The murine VLDL receptor
was expressed in the livers of mice deficient in LDL recep-
tor by using a first-generation adenovirus; LDL cholesterol
levels were reduced to a comparable degree and for a
longer period compared with the expression of the LDL
receptor [14]. A recombinant adeno-associated virus
(AAV) was used to express the murine VLDL receptor inCurrent Controlled Trials in Cardiovascular Medicine    Vol 1 No 2 Kawashiri and Rader
the livers of mice deficient in LDL receptor fed on a high-fat
Western diet. Expression of the VLDL receptor decreased
plasma cholesterol levels significantly for more than
7 months and reduced the development and progression
of atherosclerosis [15]. Another novel approach is the use
of chimeric molecules made by fusion of a soluble form of
the LDL receptor with transferrin [16] that could potentially
bind LDL in the circulation and mediate clearance through
the transferrin receptor on hepatocytes.
Homozygous FH is the only lipid disorder that has been
approached in a clinical gene therapy trial [17]. The trial
used an ex vivo approach in which five homozygous FH
patients underwent a surgical resection of the left lateral
segment of the liver. Primary hepatocytes were isolated
and after 2 days were infected with a recombinant retro-
virus encoding the human LDL receptor gene. The geneti-
cally modified hepatocytes were harvested 24 h later and
reinfused into the patients via a portal catheter that was
placed in the inferior mesenteric vein at the time of the
original surgery. Patients tolerated the infusions of autolo-
gous hepatocytes well without complications. Two of five
patients had a decrease of about 20% in their LDL choles-
terol levels. Kinetic studies of LDL metabolism demon-
strated that LDL catabolism was increased in the same
two patients, which was consistent with increased LDL
receptor expression. Liver biopsies performed 4 months
after treatment revealed LDL receptor transgene expres-
sion by in situ hybridization in all five subjects.
Homozygous FH will continue to be a model for the devel-
opment of liver-directed somatic gene therapy. However,
many heterozygous FH patients are also relatively refractory
to existing drug therapy and remain at very high risk for
development and progression of atherosclerotic vascular
disease. Therefore, once a gene therapeutic strategy is
found to be effective in homozygous FH, it might be
extended to clinical trials in severe heterozygous FH as well.
Lipoprotein lipase deficiency (familial hyperchylomicronemia)
Lipoprotein lipase (LPL) deficiency is a rare autosomal
recessive disorder characterized by markedly elevated
plasma levels of triglycerides [18]. Normally, triglycerides in
chylomicrons are hydrolyzed by LPL, and the genetic
absence of LPL results in marked hyperchylomicronemia.
LPL deficiency is associated with recurrent episodes of
acute pancreatitis, which can be life-threatening and can
also lead to chronic pancreatic insufficiency. LPL defi-
ciency is often refractory to diet and drug therapy and is
therefore a candidate for the development of gene therapy.
Several animal models of LPL deficiency exist. LPL knock-
out mice have severe hypertriglyceridemia and die within
24 h of birth [19]. Germline transgenic expression of LPL
in skeletal muscle rescued the mice and normalized the
triglyceride levels [20]. Cats and minks that are naturally
deficient in LPL have been reported [21,22]. Liver-
directed overexpression of human LPL with an adenoviral
vector in LPL-deficient cats reduced triglyceride levels for
up to 14 days [23].
Most LPL expression is in muscle and adipose tissue.
Because skeletal muscle is an attractive target for somatic
gene transfer, LPL deficiency is a candidate for the devel-
opment of muscle-directed gene therapy. The intramuscu-
lar injection of recombinant AAV vectors in mice resulted
in the stable expression of several secreted proteins
[24–26]. Correction of hemophilia B was achieved by the
intramuscular injection of an AAV vector in dogs [27] and
in humans [28]. AAV might therefore be an attractive
vector for the use of muscle-directed LPL gene transfer.
The major issues are whether enough LPL expression
could be achieved to normalize triglyceride levels and the
duration of gene expression.
Gene transfer to increase LPL expression could potentially
have therapeutic value in conditions other than homozygous
LPL deficiency. Transgenic mice overexpressing LPL have
less diet-induced hyperlipidemia, less hyperlipidemia associ-
ated with diabetes, and reduced diet-induced atherosclero-
sis. Liver-directed gene transfer of LPL with recombinant
adenovirus decreased fasting and post-prandial levels of
triglycerides in heterozygous LPL-deficient mice [29] and
decreased levels of triglycerides and cholesterol in mice defi-
cient in apolipoprotein E (apoE) and in LDL receptor [30].
ApoE deficiency and familial dysbetalipoproteinemia
ApoE serves as a ligand that mediates the clearance of
chylomicron and VLDL remnant lipoproteins by binding to
the LDL receptor and related members of the same gene
family [31]. Most apoE in plasma is derived from the liver.
A genetic deficiency of apoE results in substantially ele-
vated levels of lipoprotein remnants and is associated with
an increased risk for atherosclerotic vascular disease [32].
ApoE knockout mice develop high levels of remnant
lipoproteins and severe atherosclerosis on a chow diet
[33]. Liver-directed gene transfer of human apoE markedly
decreased plasma cholesterol levels for about 2 weeks
with a first-generation adenovirus [34,35] and for at least
8 weeks with a second-generation adenovirus [36]. Gene
transfer of apoE to the liver in apoE-deficient mice also
induced substantial regression of atherosclerosis [37,38].
Although plasma apoE is mostly derived from the liver,
apoE produced in any tissue could theoretically be effec-
tive if secreted into the blood. ApoE derived from
macrophages after transplantation of wild-type bone
marrow into apoE-deficient mice also normalized plasma
cholesterol levels and reduced the development of athero-
sclerosis [39]. ApoE gene therapy in patients with apoE
deficiency would correct the hyperlipidemia but this condi-
tion is extremely rare and is therefore not an optimal model
for the development of this type of gene therapy.ApoE gene therapy could have therapeutic value in
another apoE-related lipid disorder sometimes called
familial dysbetalipoproteinemia or Type III hyperlipopro-
teinemia [40]. In this disorder, a mutant apoE has
decreased binding to receptors, thus resulting in a
reduced clearance of remnant lipoproteins and hyperlipi-
demia. The most common cause is homozygosity for a
common polymorphism in apoE called apoE2 (the wild-
type form is known as apoE3). Rarer causes are other
apoE mutations that often cause hyperlipidemia in a domi-
nant fashion. Gene therapy to increase the hepatic pro-
duction of wild-type apoE3 could be a therapeutic
strategy for this condition.
Familial combined hyperlipidemia and diabetic dyslipidemia
Familial combined hyperlipidemia is an inherited pheno-
type characterized by elevated VLDL and LDL; it is
believed to be normally due to overproduction of VLDL by
the liver [41]. The specific genetic basis of this common
disorder is currently unknown. Type II diabetes mellitus is
also characterized by the hepatic overproduction of VLDL
and increased VLDL and LDL cholesterol [42]. Both of
these conditions are associated with a significantly
increased risk for atherosclerotic vascular disease.
Although many patients with these disorders can be ade-
quately treated with lifestyle and drug therapy, a substan-
tial number cannot achieve adequate control of their
hyperlipidemia. Gene therapy might therefore be one ther-
apeutic approach to this class of patients with refractory
combined hyperlipidemia.
One approach could be expression of the VLDL receptor in
the liver. As noted above, although the VLDL receptor is
not normally expressed in the liver, it could theoretically
bind VLDL and reduce the levels of both VLDL and LDL.
Proof-of-principle studies in relevant animal models are
needed to address this question. Another approach could
be increasing the hepatic expression of apoE. Because
apoE serves as a ligand for the LDL receptor, other related
receptors, and heparan sulfate proteogycans in the liver,
increased apoE expression could potentially target more
VLDL and remnants for hepatic degradation, thus reducing
VLDL and LDL levels. Again, proof-of-principle studies in
relevant animal models are needed to address this ques-
tion. Specifically, more data are needed on the effects of
hepatic apoE gene transfer on lipoprotein metabolism in
dyslipidemic animal models other than apoE deficiency.
Disorders associated primarily with low-HDL cholesterol
Lecithin : cholesterol acyltransferase deficiency
Unesterified cholesterol is esterified to cholesteryl ester in
the blood by the lipoprotein-associated enzyme lecithin:
cholesterol acyltransferase (LCAT). Complete LCAT
deficiency is is characterized by markedly reduced HDL
cholesterol levels (less than 10 mg/dl), corneal opacities,
anemia, and progressive proteinuria and renal insufficiency
eventually leading to end-stage renal disease [43]. Several
different mutations in the LCAT gene have been described
in patients with LCAT deficiency. LCAT knockout mice
also have reduced HDL cholesterol levels [44], although
the development of renal disease has not been reported.
Because this disorder has no known therapy to prevent
the progressive renal disease, it is a candidate for the
development of gene therapy. Although LCAT is normally
synthesized in the liver, because it is a secreted protein it
could theoretically be made in other tissues such as
muscle after gene transfer.
Tangier disease
Tangier disease is a rare genetic disorder associated with
markedly reduced HDL cholesterol levels (less than 5
mg/dl), the accumulation of cholesterol in macrophages
and related cells, neuropathy, and premature atherosclero-
sis [45]. It is caused by mutations in the ATP-binding cas-
sette protein 1 (ABC1), a cellular protein that promotes
the efflux of cellular cholesterol and phospholipids to
nascent HDL and lipid-poor apolipoprotein A-I (apoA-I)
[46]. ABC1 knockout mice also have markedly reduced
HDL cholesterol levels and cholesterol storage in
macrophages and macrophage-like cells [47]. A naturally
occurring model of Tangier disease in chickens has been
reported [48]. Gene transfer of ABC1 to macrophages or
bone marrow stem cells would be likely to ameliorate the
symptoms of this disorder, but no proof-of-principle
studies have yet been reported in animals.
Importantly, heterozygotes for ABC1 mutations have sig-
nificantly reduced HDL cholesterol levels (less than 10th
percentile) [49] and are at increased risk for atheroscle-
rotic vascular disease [50]. There are no drug therapies
that raise HDL cholesterol levels in these patients.
Macrophage-directed gene therapy with ABC1 could
therefore be an approach to this disorder as well.
ApoA-I deficiency
ApoA-I is the major protein in HDL; a genetic deficiency of
apoA-I results in markedly reduced HDL and seems, at
least in some kindreds, to increase the risk for coronary
artery disease [51]. ApoA-I knockout mice have extremely
low levels of HDL cholesterol and although chow-fed mice
do not develop atherosclerosis [52], the absence of apoA-
I enhances the progression of atheroclerosis in hyperlipi-
demic mouse models [53,54]. The expression of human
apoA-I in apoA-I knockout mice by using a first-generation
adenovirus transiently restored HDL cholesterol levels to
the normal range [55]. In apoA-I-deficient patients, gene
transfer of apoA-I to liver (or possibly muscle) would be
expected to increase HDL cholesterol levels and over time
would reduce the risk for atherosclerotic disease.
However, apoA-I-deficient patients are very rare, making
this disease somewhat less attractive as a target for the
development of gene therapy.
http://cvm.controlled-trials.com/content/1/2/120
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Reduced levels of HDL cholesterol are common, and most
patients with low HDL do not have mutations in LCAT,
ABC1, or apoA-I. However, it is possible that gene transfer
to express any of these genes could nevertheless be thera-
peutically useful. For example, by converting unesterified to
esterified cholesterol, LCAT is believed to facilitate the
process of ‘reverse cholesterol transport’. Transgenic over-
expression of human LCAT increased HDL cholesterol
levels in mice [56–58] and rabbits [59,60]. Administration
of a first-generation adenovirus encoding human LCAT in
human apoA-I transgenic mice resulted in a substantial
increase in HDL cholesterol and human apoA-I levels [61].
Although transgenic LCAT overexpression increased ather-
osclerosis in cholesterol-fed mice [62], co-expression with
cholesteryl ester transfer protein (CETP) reduced athero-
sclerosis in mice [63]. Furthermore, transgenic expression
of LCAT in cholesterol-fed rabbits reduced atherosclerosis
[64]. Thus, LCAT might be a candidate for gene therapy to
inhibit atherosclerosis in humans. Similarly, gene therapy to
augment ABC1 expression in macrophages might be
expected to reduce atherosclerosis even in patients who
do not have ABC1 mutations. Animal experiments are
needed to test this hypothesis.
Perhaps the best evidence for this concept exists for
apoA-I. A variety of evidence in animals indicates that
intervention to increase the expression of apoA-I is likely to
be associated with reduced atherosclerosis. Weekly intra-
venous injection of human HDL into cholesterol-fed
rabbits resulted in the regression of atherosclerotic
lesions [65] and regular intravenous injection of rabbit
apoA-I into cholesterol-fed rabbits resulted in the reduced
progression of atherosclerotic lesions [66]. Hepatic over-
expression of human apoA-I in trangenic mice reduced
atherosclerosis in C57BL/6 mice fed with a high-fat diet
[67] and in apoE-deficient mice [68,69]. Transgenic over-
expression of human apoA-I in the livers of hyperlipidemic
WHHL rabbits reduced the development of aortic athero-
sclerosis [70]. Gene transfer of human apoA-I with a first-
generation adenoviral vector in human apoA-I-transgenic/
apoE-deficient mice reduced the progression of athero-
sclerosis [71]. Administration of a second-generation
adenovirus resulted in the significant regression of pre-
existing atherosclerotic lesions in mice deficient in low-
density lipoprotein receptor that were fed with a Western
diet [72]. These results indicate the feasibility of apoA-I
gene transfer as a strategy for affecting atherosclerosis.
ApoE is another candidate for gene transfer and overex-
pression as a strategy to reduce atherosclerosis [73].
Other disorders associated with defects in lipid and
lipoprotein metabolism
Wolman disease and cholesteryl ester storage disease
Lysosomal acid lipase (LAL) is required for the hydrolysis
of lipoprotein-derived cholesteryl esters and triglycerides
in the lysosome. Wolman disease and cholesteryl ester
storage disease are autosomal recessive disorders
caused by mutations in LAL. Wolman disease is the rare
and more severe form in which infants develop hepato-
splenomegaly, steatorrhea, adrenal calcification, failure to
thrive, and early death by the second year of life. Patients
with cholesteryl ester storage disease have hepatomegaly
and hyperlipidemia in childhood and often progress to
fibrotic liver disease. The reason for the differences in phe-
notype might be related to the specific molecular defects
underlying the LAL deficiency [74]. A natural rat model of
this disorder [75] and the acid lipase knockout mouse
[76] each have many of the pathologic features of the
human disease. Correction of the LAL deficiency in fibrob-
lasts obtained from Wolman disease patients by using a
recombinant adenovirus reduced the lipid storage and
increased cell growth [77]. LAL deficiency disorders are
attractive for gene therapy because the restoration of a
relatively small amount of LAL expression in the liver would
be expected to ameliorate the disease.
Abetalipoproteinemia
The microsomal transfer protein (MTP) mediates the
microsomal transport of lipids in the intestine and liver and
is necessary for the normal formation and secretion of chy-
lomicrons in the enterocyte and VLDL in the hepatocyte
[78]. Abetalipoproteinemia is a rare autosomal recessive
disease caused by mutations in MTP. Abetalipoproteine-
mia is characterized by progressive spinocerebellar
degeneration and pigmented degenerative retinopathy,
leading to severe ataxia, blindness, and eventually prema-
ture death. These symptoms are the result of defects in
the absorption and transport of fat-soluble vitamins, espe-
cially vitamin E, which requires the VLDL–LDL system for
adequate transport to peripheral tissues. Therapy with
high-dose vitamin E and other fat-soluble vitamins can
slow but not prevent the progression of these symptoms.
Knockout of MTP is lethal during embryogenesis [79] but
the MTP gene was deleted in the liver after birth, creating
a mouse model of hepatic MTP deficiency [80]. A recom-
binant adenovirus was used to overexpress MTP in wild-
type mice, resulting in increased hepatic VLDL production
[81]. Abetalipoproteinemia is an attractive candidate for
the development of gene therapy, because even a rela-
tively low level of MTP expression in the liver would be
expected to result in some VLDL production and therefore
a substantial improvement in vitamin E transport and
potentially slowing or halting the progression of neurologi-
cal and retinal symtoms.
Issues relevant to the development of gene
therapy for lipid disorders
Effective gene therapy for the lipid disorders described
above will require stable gene expression. Recent
progress in vector development has focused on the devel-
opment of vectors with a potential for long-term expres-
Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 2 Kawashiri and Radersion. Recombinant adenoviral vectors elicit a cellular
immune response to adenoviral proteins, limiting gene
expression and posing safety issues. Helper-dependent
adenoviruses are fully deleted of adenoviral genes, thus
removing the trigger of the immune response. A single
intravenous injection of helper-dependent adenovirus
results in less hepatotoxicity and considerably longer
hepatic expression than earlier-generation adenoviral
vectors [82]. Neutralizing antibodies against adenoviral
capsid proteins are also generated by the injection of
recombinant adenoviruses, preventing successful re-
administration [83]. Transient immunosuppression at the
time of vector administration permits subsequent adminis-
tration and repeat transgene expression in liver [84]. The
use of different adenoviral serotypes might also provide a
strategy for overcoming neutralizing antibodies [85].
Recombinant AAV is an attractive vector for gene transfer
because, like the helper-dependent adenovirus, it does not
contain sequences encoding viral proteins [86]. Gene
expression in the liver by using AAV vectors is dependent
on the promoter [87]. AAV was used to express human
factor IX in liver at therapeutic concentrations providing the
stable correction of hemophilia B in mice and dogs [88,89].
AAV was also used to express human factor IX in muscle to
achieve therapeutic plasma concentrations in mice, dogs,
and humans [28]. Although AAV is promising, higher levels
of gene expression will probably be required for the therapy
of most of the lipid disorders described above.
Conclusion
Lipid disorders are common and associated with serious
consequences such as atherosclerotic vascular disease
and others specific to individual disorders. Current
approaches to the treatment of lipid disorders are effective
in many but not all patients. New approaches to refractory
hypercholesterolemia, severe hypertriglyceridemia, low
levels of HDL cholesterol, and certain inherited disorders
of intracellular lipid metabolism are needed. Somatic gene
therapy is a viable approach to the therapy of several lipid
disorders for which therapies are currently inadequate.
The molecular etiology and pathophysiology of most of the
candidate diseases are very well understood. Animal
models exist for the diseases and in many cases preclini-
cal proof-of-principle studies have already been per-
formed. In contrast with many other situations,
overexpression of the therapeutic gene is unlikely in most
cases to have any deleterious consequences and thus
regulated expression is not required. Finally, many of the
same genes that could be used to treat genetic deficiency
disorders are also attractive candidates for genetic overex-
pression in persons who do not have a specific gene defi-
ciency disorder but who have other causes of severe
hyperlipidemia or low-HDL cholesterol. There has been
progress in the development of vectors with less immuno-
genicicity that provide long-term gene expression. The
next decade is therefore likely to witness several clinical
trials of gene therapy for lipid disorders.
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